AecorBio Appoints Prof. Karl G. Sylvester, M.D., as Co-Founder and Consulting Chief Medical Officer
Stanford physician-scientist and clinical research leader to direct clinical development of FT-002a-O, AecorBio’s oral co-treatment for ARPI-resistant metastatic castration-resistant prostate cancer (mCRPC), as the company advances toward IND submission and a Phase 1b trial
MENLO PARK, California, November 3, 2026 — AecorBio Inc., an IND-stage biopharmaceutical company developing oral peptide treatments that restore sensitivity to standard cancer therapies, today announced the appointment of Prof. Karl G. Sylvester, M.D., as Co-Founder and Consulting Chief Medical Officer, effective October 1, 2026. Dr. Sylvester has advised AecorBio on the clinical strategy for its lead program since late 2025 and will now lead the company’s clinical development, including the design and execution of the planned Phase 1b trial of FT-002a-O in mCRPC, the company’s investigator and clinical site relationships, and the clinical and medical content of all AecorBio programs. He reports to Bomi Framroze, Ph.D., Chief Executive Officer and Co-Founder.
“Karl has helped shape the FT-002a-O clinical strategy from the beginning, and formalizing his role as a co-founder reflects both that contribution and the central place clinical execution now holds for the company,” said Dr. Framroze. “He brings exactly what we need as we move from preclinical development into the clinic: rigor in trial design, a deep working knowledge of how clinical and translational research actually gets done inside a leading academic medical center, and a shared conviction that treatment resistance is a problem worth solving.”
Dr. Sylvester is Professor of Surgery (Pediatric Surgery) at Stanford University School of Medicine. In 2025 he was appointed Chief Research Operations Officer of Stanford Medicine Children’s Health, with responsibility for integrating research with clinical operations and removing barriers to the conduct of clinical and translational research across the University. He has designed and overseen the infrastructure that supports investigator-initiated and industry-sponsored clinical studies at Stanford, and he has served as an advisor to multiple early-stage life science companies.
“FT-002a-O addresses a question every oncologist treating advanced cancer faces: what to do when a therapy that was working stops working,” said Dr. Sylvester. “The preclinical data show that adding FT-002a-O can restore the activity of an androgen receptor pathway inhibitor in a prostate tumor that has become resistant to it, and the FDA’s pre-IND feedback has given us a clear path to test that in patients. I am delighted to take on this role and to help carry the program through its first clinical study.”
AecorBio enters the final quarter of 2026 with its lead program on track and the key building blocks for an Investigational New Drug (IND) application in place. In September 2026 the company received the U.S. Food and Drug Administration’s written response to its pre-IND meeting request for FT-002a-O in mCRPC. The Agency’s feedback is supportive of the company’s first-in-human Phase 1b design, in which FT-002a-O is added to the androgen receptor pathway inhibitor (ARPI) a prostate cancer patient is already receiving, with dose selection guided by pharmacodynamic biomarkers and PSA kinetics providing an early clinical signal.
The company has confirmed the mechanism of action in multiple in vivo models of acquired ARPI resistance, in which FT-002a-O restored tumor control when combined with an ARPI that had stopped working on its own. AecorBio expects to submit the IND in 2027 and to open the Phase 1b study at Stanford University, with additional U.S. sites to follow.
AecorBio has launched its new corporate website at www.aecorbio.com. The site describes the company’s approach to treatment resistance, the FT-002a-O program and its scientific rationale, the leadership team and the development roadmap. Going forward, the website will be AecorBio’s primary channel for company news, program milestones, publications and presentations, and investors, partners and clinicians are invited to visit the site for the latest information on the company.
About AecorBio
AecorBio Inc. is an IND-stage biopharmaceutical company based in Menlo Park, California, developing oral peptide treatments that target treatment resistance in cancer and other diseases. The company’s lead program, FT-002a-O, is being developed as a co-treatment for ARPI-resistant metastatic castration-resistant prostate cancer, with earlier-stage programs in co-treatment of other solid tumors. AecorBio works in close strategic partnership with Hofseth BioCare ASA (Oslo Stock Exchange: HBC). For more information, visit www.aecorbio.com.
Forward-looking statements
This release contains forward-looking statements, including statements regarding the timing of regulatory submissions, the initiation and design of clinical trials, and the potential benefits of FT-002a-O. These statements are based on current expectations and are subject to risks and uncertainties, including those inherent in drug development and regulatory review. Actual results may differ materially. AecorBio undertakes no obligation to update these statements.
Contacts
Bomi Framroze, Ph.D., Chief Executive Officer and Co-Founder — bf@aecorbio.com
Karl G. Sylvester, M.D., Consulting Chief Medical Officer and Co-Founder — kgs@aecorbio.com
Crawford Currie, Strategic Advisor — cc@aecorbio.com
###